<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Veradermics, Incorporated — News on 6ix</title>
    <link>https://6ix.com/company/veradermics-incorporated</link>
    <description>Latest news and press releases for Veradermics, Incorporated on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 30 Apr 2026 02:32:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/veradermics-incorporated" rel="self" type="application/rss+xml" />
    <item>
      <title>Veradermics Announces Pricing of Upsized Public Offering and Private Placement</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-pricing-of-upsized-public-offering-and-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-pricing-of-upsized-public-offering-and-private-placement</guid>
      <pubDate>Thu, 30 Apr 2026 02:32:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., April 30, 2026--Veradermics, Incorporated (&quot;Veradermics&quot;) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the pricing of its upsized public offering of 3,843,790 shares of its common stock at a public offering price of $100.00 per share. All of the shares are being offered by Veradermics. The gross proceeds from the offering, before deducting underwriting di</description>
    </item>
    <item>
      <title>Veradermics Announces Launch of Public Offering</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-launch-of-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-launch-of-public-offering</guid>
      <pubDate>Mon, 27 Apr 2026 21:26:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., April 27, 2026--Veradermics, Incorporated (&quot;Veradermics&quot;) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed public offering of 3,350,000 shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock) pursuant to a registration statement filed on Form S-1 wit</description>
    </item>
    <item>
      <title>Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-oral-vdphl01-achieved-early-consistent-and-robust-hair-growth-in-positive-phase-23-302-clinical-trial-in-male-pattern-hair-loss</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-oral-vdphl01-achieved-early-consistent-and-robust-hair-growth-in-positive-phase-23-302-clinical-trial-in-male-pattern-hair-loss</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., April 27, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial (Study ‘302’) evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. Veradermics b</description>
    </item>
    <item>
      <title>Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-to-hold-conference-call-to-discuss-topline-results-from-phase-23-302-study-of-vdphl01-in-males-with-mild-to-moderate-pattern-hair-loss</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-to-hold-conference-call-to-discuss-topline-results-from-phase-23-302-study-of-vdphl01-in-males-with-mild-to-moderate-pattern-hair-loss</guid>
      <pubDate>Sun, 26 Apr 2026 20:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., April 26, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302’ clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males with mild-to-moderate patter</description>
    </item>
    <item>
      <title>Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-corporate-and-clinical-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-corporate-and-clinical-updates</guid>
      <pubDate>Mon, 30 Mar 2026 11:30:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., March 30, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today reported financial results for the fourth quarter and full year periods ended December 31, 2025, and announced recent corporate and clinical updates.</description>
    </item>
    <item>
      <title>Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-presentations-on-vdphl01-and-patient-experiences-with-pattern-hair-loss-at-2026-american-academy-of-dermatology-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-presentations-on-vdphl01-and-patient-experiences-with-pattern-hair-loss-at-2026-american-academy-of-dermatology-annual-meeting</guid>
      <pubDate>Wed, 18 Mar 2026 11:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., March 18, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026.</description>
    </item>
    <item>
      <title>Veradermics to Participate in Upcoming March Investor Conferences</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-to-participate-in-upcoming-march-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-to-participate-in-upcoming-march-investor-conferences</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., March 03, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March:</description>
    </item>
    <item>
      <title>Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-completes-enrollment-in-second-pivotal-phase-3-clinical-trial-of-vdphl01-for-male-pattern-hair-loss</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-completes-enrollment-in-second-pivotal-phase-3-clinical-trial-of-vdphl01-for-male-pattern-hair-loss</guid>
      <pubDate>Mon, 09 Feb 2026 12:30:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., February 09, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics’ first Phase 2/</description>
    </item>
    <item>
      <title>Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-closing-of-full-exercise-of-underwriters-option-to-purchase-additional-shares-in-initial-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-closing-of-full-exercise-of-underwriters-option-to-purchase-additional-shares-in-initial-public-offering</guid>
      <pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., February 05, 2026--Veradermics, Incorporated (&quot;Veradermics&quot;), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exer</description>
    </item>
    <item>
      <title>Veradermics Announces Pricing of Upsized Initial Public Offering</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-pricing-of-upsized-initial-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-announces-pricing-of-upsized-initial-public-offering</guid>
      <pubDate>Wed, 04 Feb 2026 02:57:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., February 04, 2026--Veradermics, Incorporated (&quot;Veradermics&quot;), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. The gross proceeds fr</description>
    </item>
  </channel>
</rss>